Skip to content

4564.T

OncoTherapy Science,Inc.

グロース · 医薬品 · 医薬品 · JP

JPY 17.00
−5.56%
Ask drillr

Year over year

Reported trailing growth

Revenue
+10.9%
EBITDA
—
EBIT
+6.3%
EPS
+29.7%
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
—

Three-year CAGR

Revenue
-13.4%
EBITDA
—
EBIT
+28.8%
Net income
+36.7%
EPS
+48.4%
Free cash flow
+33.7%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026